Brought to you by 
Genentech options rights to Exelixis' XL518; exercised
11 Nov 2021
Executive Summary
Genentech has signed a deal granting it options to globally develop Exelixis' (small-molecule therapeutics for cancer) XL518, for which Exelixis filed an IND just a few days before the alliance was announced. The candidate inhibits MEK (mitogen-activated protein kinase, MAPK), which plays a major role in the RAS/RAF/MEK/ERK pathway often activated in tumors.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
- Trial Collaborations
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech options rights to Exelixis' XL518; exercised
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice